her2 positive breast cancer ihc

Release time ：Nov-11,2024

HER2-positive breast cancer is a distinct subtype of breast cancer, defined by the excessive expression of a protein known as HER2 (human epidermal growth factor receptor 2) on the surface of cancer cells. This subtype is typically more aggressive than other forms of breast cancer and has a higher propensity for spreading to other parts of the body. Diagnosis usually involves immunohistochemistry (IHC) testing to confirm the overexpression of the HER2 protein in cancer cells.

Treatment for HER2-positive breast cancer may include targeted therapies, which often involve drugs that specifically target the HER2 protein. Depending on the patient's unique circumstances, a combination of chemotherapy, radiotherapy, and endocrine therapy may also be employed. The selection of a treatment plan is influenced by the tumor’s specific characteristics, the patient’s overall health, and the tumor’s clinical stage.

For patients diagnosed with HER2-positive breast cancer, it is crucial to collaborate closely with the healthcare team to understand all treatment options available and to adhere to the physician’s recommendations. Additionally, maintaining a healthy lifestyle, including a balanced diet, regular exercise, and abstaining from smoking, can contribute to better treatment outcomes and quality of life. Always remember that any treatment should be conducted under a doctor's supervision and never self-administer medications or alter the treatment plan without professional guidance.